JULIPTA Trademark

Trademark Overview


On Friday, September 16, 2016, a trademark application was filed for JULIPTA with the United States Patent and Trademark Office. The USPTO has given the JULIPTA trademark a serial number of 87174410. The federal status of this trademark filing is ABANDONED - EXPRESS AFTER PUB as of Thursday, April 30, 2020. This trademark is owned by Allergan Sales, LLC. The JULIPTA trademark is filed in the Pharmaceutical Products category with the following description:

Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines affecting sensory organs; Pharmaceuticals and medicines affecting the central nervous system; Pharmaceuticals a...
julipta

General Information


Serial Number87174410
Word MarkJULIPTA
Filing DateFriday, September 16, 2016
Status605 - ABANDONED - EXPRESS AFTER PUB
Status DateThursday, April 30, 2020
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 31, 2017

Trademark Statements


Goods and ServicesOral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines affecting sensory organs; Pharmaceuticals and medicines affecting the central nervous system; Pharmaceuticals and medicines affecting urogenital organs; Pharmaceuticals and medicines affecting circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular and blood pressure diseases and disorders; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression; Pharmaceuticals, namely, neuroprotective agents; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical preparations for skin care used in connection with anti-aging, the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, facial aesthetic surgery, facial aesthetic reconstruction, breast aesthetics; topical antibiotics, anti-inflammatories, anti-infectives, anti-glaucoma eye drops and decongestant formulations; sterile ointments for medical use; ocular wetting solutions, artificial tears and formulations pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lighteners; Pharmaceuticals and cosmeceuticals, namely, medicated skin cleansers, toners, moisturizers, skin rejuvenators, rehydrating creams, and lotions for the face and body

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code8 - Abandoned
Class Status DateThursday, April 30, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAllergan Sales, LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressMadison, NJ 07940

Party NameAllergan Sales, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressParsippany, NJ 07054

Trademark Events


Event DateEvent Description
Thursday, April 30, 2020ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION
Thursday, April 30, 2020ABANDONMENT - AFTER PUBLICATION
Wednesday, April 29, 2020TEAS EXPRESS ABANDONMENT RECEIVED
Wednesday, September 25, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, September 24, 2019EXTENSION 5 GRANTED
Friday, September 20, 2019EXTENSION 5 FILED
Tuesday, September 24, 2019CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, September 20, 2019TEAS EXTENSION RECEIVED
Tuesday, March 5, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, March 1, 2019EXTENSION 4 GRANTED
Friday, March 1, 2019EXTENSION 4 FILED
Friday, March 1, 2019TEAS EXTENSION RECEIVED
Tuesday, September 11, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, September 7, 2018EXTENSION 3 GRANTED
Friday, September 7, 2018EXTENSION 3 FILED
Friday, September 7, 2018TEAS EXTENSION RECEIVED
Thursday, February 1, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, January 30, 2018EXTENSION 2 GRANTED
Tuesday, January 30, 2018EXTENSION 2 FILED
Tuesday, January 30, 2018TEAS EXTENSION RECEIVED
Friday, August 18, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 16, 2017EXTENSION 1 GRANTED
Wednesday, August 16, 2017EXTENSION 1 FILED
Wednesday, August 16, 2017TEAS EXTENSION RECEIVED
Tuesday, March 28, 2017NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Saturday, March 4, 2017CHANGES/CORRECTIONS AFTER PUB APPROVAL ENTERED
Friday, March 3, 2017ASSIGNED TO PETITION STAFF
Thursday, February 16, 2017TEAS POST PUBLICATION AMENDMENT RECEIVED
Tuesday, January 31, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 31, 2017PUBLISHED FOR OPPOSITION
Wednesday, January 11, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, December 22, 2016APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, December 21, 2016ASSIGNED TO EXAMINER
Wednesday, September 21, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Tuesday, September 20, 2016NEW APPLICATION ENTERED IN TRAM